| Biotechnology
Investment Today Biotechnology Investment Today (B.I.T.) provides industry stakeholders, both scientists and financers, with original and relevant data, information and knowledge on all aspects of the biotechnology industry. To this end, the company has developed a highly respected product portfolio, comprising its magazine, which reaches over 80,000 readers annually, its series of BioBusiness seminars and its website. The B.I.T. magazine reaches a global audience of senior decision-makers and provides them with thought-provoking, timely and qualitative insights to critical industry issues. The content originates from industry leaders, government policy makers, market makers and analysts. It is our mission to serve the growing need for constantly updated information by Biotech CEOs and those in equivalent positions, institutional investors and venture capitalists eager to identify new and exciting business opportunities. The renowned and highly acclaimed BioBusiness Seminar Series ensure that B.I.T. continue to maintain and further develop close relationships with the principal stakeholders in the industry. The seminars enable investors to immerse themselves in an environment which encourages, and is conducive to senior management meetings. The relaxed format allows questions to be openly asked and the conclusions drawn on company potential facilitate real business development. Our website enables users to locate information regarding new scientific and financial developments quickly and easily providing them with an invaluable aid in identifying new investment opportunities. Our mission is to help companies by providing platforms that inspire confidence in the sector. In summary, B.I.T. enables industry stakeholders to source information and forge productive business relationships with Biotech CEOs, Big Pharma alliance managers, legal firms, professional service providers and venture capitalists. We provide the stakeholders with a series of intelligent platforms that allow critical data, information and knowledge dissemination. We ensure that the experiences within the industry are correctly represented in a qualitative and timely manner in order that they have maximum impact in facilitating the often complicated, always crucial, senior decision-making processes. |
 |
|
BusinessWire Business Wire is the global leader in news distribution, delivering more news from more sources to more destinations than any other service in the world. A trusted partner to tens of thousands of companies and organizations throughout the world, Business Wire delivers your news releases and multimedia simultaneously to media, analysts and financial professionals, online communities and targeted audiences based on your specifications. For additional information visit WWW.BUSINESSWIRE.COM or call US +310.820.8473 ext. 602 or in Europe +44.20.7626.1982 |
 |
|
Citigate Dewe Rogerson Citigate Dewe Rogerson (CDR) is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. CDR is a member of Incepta Group plc, the international marketing and communications group. With Headquarters based in London, Incepta Group operates out of 78 offices in 18 countries worldwide. Incepta Group currently employs over 2,000 members of staff and services circa 3,000 clients. CDR has a dedicated Pharma & Biotech team with more than 30 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from CDR’s overall strength and from the cross-fertilisation of ideas across sectors. The CDR Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. |
 |
|
Finance FINANCE is a monthly magazine published by FINANCIAL Gates GmbH, part of the Frankfurter Allgemeine Zeitung GmbH publishing group. It is the premier authoritative publication on all aspects of corporate finance in Germany. Topics covered include mergers and acquisitions, venture capital, stock market listings, buy-outs and private equity. FINANCE focuses in particular on issues of relevance to German medium-sized and start-up companies. FINANCE is also read by the M&A and corporate finance experts of major companies. The guaranteed monthly circulation is 25,000 copies. For subscriptions please call +49 40 3007 25 34, or fax +49 40 3007 3070. |
 |
|
GoingPublic Media AG Founded in 1998 GoingPublic Media AG is today one of the leading companies in Germany publishing magazines on venture capital and corporate finance contents as well as small and mid cap research. In addition to the monthly issued GoingPublic Magazin and its well known yearly special editions like “Corporate Finance & Private Equity Guide”, “Biotechnology “or “Investor Relations” which are largely meant as reference books, the company publishes the likewise monthly VentureCapital Magazin. Founded in 2000 as a supplement to the GoingPublic Magazin, VentureCapital Magazin (www.venturecapital.de) started into a new era as an independent publication in July 2002 and focuses on private equity, buy-outs and M&A. The brand is a synonym for growth, innovation, entrepreneurial culture and equity financing. Special topics are additionally treated in supplements and special editions (“Nanotechnology”, “Mittelstandsfinanzierung” etc). Furthermore GoingPublic Media operates the online-service GoingPublic Online (www.goingpublic.de) and the corporate publishing division (GoingPublic Services) publishes about 10 magazines and newsletters a year for well-known venture capital companies and financial institutions. Since May 2003 the company publishes a third magazine called “Smart Investor” (www.smartinvestor.de). With its critical research and independent thinking, Smart Investor is an ambitious, fast growing magazine for the contrarian investor seeking information beyond the mainstream. All publications are printed in German. Contact: Orders and subscriptions: For more information, please contact us at +49-8171-419650 or info@goingpublic.de |
 |
LifeSciChannel – Science for a Digital Age LifeScienceChannel.com is the pre-eminent interactive online forum for the global scientist. Focusing predominantly on the health sciences, LifeScienceChannel.com provides an enhanced multimedia solution for the dissemination of first class academic and professional information that cannot be captured in traditional print form. Established by Prous Science, LifeScienceChannel.com provides exclusive access to an expanding archive of live conferences, seminars, lectures, talks and interviews from leading industry and academic experts in the health sciences. In addition, news, views and critical opinion articles ensure that LifeScienceChannel.com provides a complete and relevant information service. This growing library of information is uniquely searchable through MAVS (Multilingual Audio Visual Search), a technology that enables full search and indexing of audio and visual files, from streamed television quality conference talks to the simple spoken word. The combination of a powerful archive of presentations captured by professional production teams with the ability to key word search for personal interest, makes LifeScienceChannel.com a first class information forum for the health science expert. LifeScienceChannel.com provides a multimedia forum for representatives from academia and commerce to showcase latest advances through the use of the latest web technology. Capable of supporting Internet2 level communication, LifeScienceChannel.com offers key advantages to collaborations between academia and industry. The Prous Science Broadcasting Division, publisher of LifeSciChannel.com, is headed by a team of broadcasting professionals and supported by experienced film crews based around the world, to increase the potential for global coverage of the latest conferences and events. For further information or to establish an online
company profile, contact Jaci Fluker, Prous Science Broadcasting Division |
 |
| Maitland Noonan
Russo Maitland Noonan Russo combines Maitland’s established strengths in Financial PR with those of Euro RSCG Life Noonan Russo, the European corporate public relations healthcare specialist to address the specific communications needs of biotechnology, medical device, and healthcare service companies throughout Europe. Maitland Noonan Russo provides strategic corporate communications counsel to healthcare companies, linking into Euro RSCG Life Noonan Russo to offer broader global marketing services. For more information contact Brian Hudspith or Emma Burdett. |
 |
|
Nature Biotechnology Nature Biotechnology is the premier peer-reviewed monthly of biotechnology, providing reviews and research reports on the research and technologies that drive biotechnological innovation wherever they are applied – in the biotechnology, pharmaceutical, agricultural and environmental industries. With an impact factor of 17.721*, Nature Biotechnology is the number one primary research journals in its field. Simply visit www.nature.com/naturebiotechnology for more information. |
|
|
Nature Reviews Drug Discovery Nature Reviews Drug Discovery is a monthly review journal that publishes authoritative, peer-reviewed articles by leaders in the field – providing a complete overview of the drug discovery and development arena, from disease mechanisms and chemistry, through to clinical development and regulatory issues. The journal, which integrates academia and industry, features cutting edge Review articles, Highlights of the latest primary papers, as well as Opinion articles and historical Perspectives. It’s first impact factor of 17.732* makes it the number one monthly review journal in its field. Visit www.nature.com/reviews/drugdisc *2003 Impact Factor: Thomson ISI, PA, USA, 2004 |
|
| Northbank Communications Profile to follow shortly. |
 |
|
The Trout Group The Trout Group provides investor relations and strategic advisory services solely to the life science industry. We have a global reach, with offices in New York, San Francisco and Boston and with advisors in Israel and Munich. Our team of professionals advises both public and private companies in the U.S., Canada, Europe, Israel and Australia. Trout’s clients include leading global biotechnology, specialty pharmaceutical, medical device and diagnostic companies. Our goal-oriented, team approach has been successful in creating and executing investor relations programs for nearly 100 companies. Intellectual Capital Relationship Capital More than anything, The Trout Group is dedicated to providing the support needed to develop the strategic plan for a company and, more importantly, working to implement the plan. We will execute the strategies we develop with our clients. Our team will not just design a plan for the Company, but we will work with the Company “hands-on” to reach our goals. What Sets The Trout Apart? |
 |